Fulcrum Therapeutics (NASDAQ:FULC) Given Neutral Rating at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a report published on Wednesday morning,Benzinga reports. HC Wainwright currently has a $4.00 target price on the stock.

Separately, Royal Bank of Canada restated a “sector perform” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Fulcrum Therapeutics has a consensus rating of “Hold” and a consensus price target of $9.33.

Fulcrum Therapeutics Price Performance

Shares of FULC opened at $3.32 on Wednesday. Fulcrum Therapeutics has a 1-year low of $2.86 and a 1-year high of $13.70. The company has a market capitalization of $179.08 million, a P/E ratio of -10.71 and a beta of 2.03. The firm’s 50 day simple moving average is $4.13 and its 200 day simple moving average is $4.62.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). On average, equities analysts anticipate that Fulcrum Therapeutics will post -0.16 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Suvretta Capital Management LLC boosted its holdings in Fulcrum Therapeutics by 182.3% during the 4th quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company’s stock valued at $15,691,000 after acquiring an additional 2,155,675 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in Fulcrum Therapeutics by 50.0% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,000,000 shares of the company’s stock valued at $14,100,000 after purchasing an additional 1,000,000 shares during the last quarter. State Street Corp boosted its stake in shares of Fulcrum Therapeutics by 61.4% during the third quarter. State Street Corp now owns 1,680,229 shares of the company’s stock valued at $5,998,000 after purchasing an additional 638,955 shares during the period. Woodline Partners LP grew its holdings in shares of Fulcrum Therapeutics by 110.3% in the fourth quarter. Woodline Partners LP now owns 1,410,520 shares of the company’s stock worth $6,629,000 after purchasing an additional 739,713 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Fulcrum Therapeutics by 1.0% in the third quarter. Geode Capital Management LLC now owns 1,320,862 shares of the company’s stock worth $4,716,000 after buying an additional 13,485 shares during the period. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.